Zentalis Pharmaceuticals, Inc. (ZNTL)
Dopo ore:
| Chiusura precedente | 23,54 |
| Aperto | 23,31 |
| Denaro | 23,00 x 1300 |
| Lettera | 37,36 x 800 |
| Min-Max giorno | 22,89 - 23,85 |
| Intervallo di 52 settimane | 17,33 - 59,65 |
| Volume | |
| Media Volume | 559.970 |
| Capitalizzazione | 1,341B |
| Beta (5 anni mensile) | 1,77 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -3,82 |
| Prossima data utili | 22 feb 2023 - 27 feb 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 52,30 |
- GlobeNewswire
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that on January 3, 2023, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 30,625 shares of the Company’s common stoc
- GlobeNewswire
Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates
Six sponsored studies with potentially first-in-class Wee1 inhibitor, ZN-c3, ongoing and continuing dose optimization work, as drug continues to show improved tolerability in initial safety data from monotherapy Phase 2 USC trial announced today Identified Cyclin E driven high-grade serous ovarian cancer patients as initial expansion population for ZN-c3 biomarker monotherapy trial Announced first ZN-c3 clinical development collaboration with Pfizer in BRAF mutant mCRC; Expanded ZN-c3 clinical d
- GlobeNewswire
Zentalis Pharmaceuticals to Participate in the Stifel 2022 Healthcare Conference
NEW YORK and SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Kimberly Blackwell, MD, Chief Executive Officer of Zentalis, will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Tuesday, November 15, 2022 at 1:15 p.m. ET.
